These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Effect of selective donor T-cell depletion on the graft-versus-leukemia reaction in allogeneic marrow transplantation. OKunewick J; Kociban D; Machen L; Buffo M Transplant Proc; 1992 Dec; 24(6):2998-9. PubMed ID: 1361270 [No Abstract] [Full Text] [Related]
9. Major and minor histocompatibility systems in man and their importance in bone marrow transplantation. van Rood JJ; van Leeuwen A Transplant Proc; 1976 Sep; 8(3):429-36. PubMed ID: 62433 [No Abstract] [Full Text] [Related]
10. The human histocompatibility complex: a review for the hematologist. Miller WV Prog Hematol; 1977; 10():173-91. PubMed ID: 337359 [No Abstract] [Full Text] [Related]
11. Association of donor-derived host-reactive cytolytic and helper T cells with outcome following alternative donor T cell-depleted bone marrow transplantation. Keever-Taylor CA; Passweg J; Kawanishi Y; Casper J; Flomenberg N; Baxter-Lowe LA Bone Marrow Transplant; 1997 May; 19(10):1001-9. PubMed ID: 9169644 [TBL] [Abstract][Full Text] [Related]
12. Immunorestoration. Good RA; Kapoor N Symp Fundam Cancer Res; 1986; 38():269-74. PubMed ID: 3529277 [No Abstract] [Full Text] [Related]
14. Major histocompatibility complex influences the development of acute graft-versus-host disease in MHC-matched adult allogeneic bone marrow transplantation. Smyth LA; Herrmann RP; Christiansen FT; Hollingsworth PN; Townend DC; Edward E; Dawkins RL Transplant Proc; 1993 Feb; 25(1 Pt 2):1276-8. PubMed ID: 8442111 [No Abstract] [Full Text] [Related]
15. Bone marrow transplantation across major histocompatibility barriers in rabbits. I. A positive role for graft-versus-host reactivity in engraftment. Adler LT; Annaratone LJ; LeBeau MM Bone Marrow Transplant; 1990 Jan; 5(1):51-6. PubMed ID: 2297590 [TBL] [Abstract][Full Text] [Related]
16. Different biology and pathology of minor alloantigen-specific cytotoxic and proliferative T cells. van Els C; Bakker A; van Rood J; Goulmy E Transplant Proc; 1991 Feb; 23(1 Pt 1):429-30. PubMed ID: 1990577 [No Abstract] [Full Text] [Related]
17. Bone marrow transplantation across major histocompatability barriers in mice. III. Treatment of donor grafts with monoclonal antibodies directed against Lyt determinants. Vallera DA; Soderling CC; Kersey JH J Immunol; 1982 Feb; 128(2):871-5. PubMed ID: 6172513 [TBL] [Abstract][Full Text] [Related]
19. The problems and practice of bone marrow transplantation in man: the severe combined immunodeficiency syndrome as the ideal model. Levey RH Transplant Proc; 1972 Dec; 4(4):565-6. PubMed ID: 4405148 [No Abstract] [Full Text] [Related]
20. Treatment of donor bone marrow with OKT3 (PAN-T monoclonal antibody) for prophylaxis of graft-vs.-host disease (GvHD) in histocompatible allogeneic bone marrow transplantation (BMT): a pilot study. Filipovich AH; McGlave P; Ramsay NK; Goldstein G; Kersey JH J Clin Immunol; 1982 Jul; 2(3 Suppl):154S-157S. PubMed ID: 6752174 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]